Home     ECG Analysis     Measurements     Safety-ECGs     Statistics     CROs     Consulting     Equipment  
 
 

Selected References

Haverkamp W, Shenasa M, Borggrefe M, Breithardt G:
Torsades de Pointes.
In: Zipes DP, Jalife J (eds): Cardiac Electrophysiology - From Cell to Bedside (2nd edition). WB Saunders Company, Philadelphia 1995; 886-899.
Reinhardt L, Mäkijärvi M, Fetsch T, Sierra G, Martinez-Rubio A, Montonen J, Katila T, Borggrefe M, Breithardt G:
Non-invasive risk modeling after myocardial infarction.
Am J Cardiol, 1996; 78: 627-632.
Abstract
Reinhardt L , Mäkijärvi M, Fetsch T, Martinez-Rubio A, Böcker D,Block M, Borggrefe M, Breithardt G:
Reduced beat-to-beat changes of heart rate: an important risk factor after acute myocardial infarction.
Cardiology 1996; 87: 104-111.
Abstract
Reinhardt L , Mäkijärvi M, Fetsch T, Montonen J, Sierra G, Martinez-Rubio A, Katila T, Borggrefe M, Breithardt G:
Predictive value of wavelet correlation functions of the signal-averaged ECG in patients after anterior and inferior myocardial infarction.
J Am Coll Cardiol 1996; 27: 53-59.
Abstract
Reinhardt L , Vesanto R, Montonen J, Fetsch T, Mäkijärvi M, Sierra G, Katila T, Breithardt G:
Localisation of myocardial infarction based on Learning Vector Quantization networks applied to ST-elevations of the 12-lead ECG.
Ann Noninvas Electrocardiol, 1997; 2: 331-337.
Eckardt, L, Haverkamp W, Borggrefe, M, and Breithardt, G:
Experimental models of torsade de pointes.
Cardiovasc Res 1998; 39:178-183. Abstract
Priori SG, Barhanin J, Hauer RN, Haverkamp W , Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde A:
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Parts I and II.
Circulation 1999; 99:518-528.
Abstract
Priori SG, Barhanin J, Hauer RN, Haverkamp W , Jongsma HJ, Kleber AG, McKenna WJ, Roden DM, Rudy Y, Schwartz K, Schwartz PJ, Towbin JA, Wilde A:
Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Part III.
Circulation 1999; 99:674-681.
Haverkamp W , Breithardt G, Janse MJ, Camm AJ, Rosen MR, Antzelevitch C, Escande D, Franz M, Malik M, Moss A, Shah R, and the other speakers in the sessions and the chairs of the workshops:
The potential for QT prolongation by non-antiarrhythmic drugs.
Clinical and regulatory implications. Report on a policy conference of the European Society of cardiology. Eur Heart J 2000; 21:1216-1231.
Haverkamp W , Mönnig G, Schulze-Bahr E, Haverkamp F, Breithardt G:
Physician-induced Torsade de Pointes - therapeutic implications.
Cardiovasc Drugs Ther. 2002; 16:101-109.
Abstract
Haverkamp W, Haverkamp F , Breithardt G:
Medikamenten-bedingte QT-Verlängerung und Torsade de Pointes: Ein multidisziplinäres Problem.
Deutsches Ärzteblatt, 2002; 99: B1662-B1668.
Full text
Smits JP, Eckardt L, Probst V, Bezzina CR, Schott JJ, Remme CA, Haverkamp W, Breithardt G, Escande D, Schulze-Bahr E, LeMarec H, Wilde AA.:
Genotype-phenotype relationship in Brugada syndrome: electrocardiographic features differentiate SCN5A-related patients from non-SCN5A-related patients.
J Am Coll Cardiol. 2002; 40:350-356.
Abstract
Milberg P, Eckardt L, Bruns HJ, Biertz J, Ramtin S, Reinsch N, Fleischer D, Kirchhof P, Fabritz L, Breithardt G, Haverkamp W:
Divergent proarrhythmic potential of macrolide antibiotics despite similar QT prolongation: fast phase 3 repolarization prevents early afterdepolarizations and torsade de pointes.
J Pharmacol Exp Ther. 2002; 303:218-225.
Abstract
Simelius K, Stenroos M, Reinhardt L , Nenonen J, Tierala I, Mäkijärvi M, Toivonen L, Katila T:
Spatiotemporal characterization of paced cardiac activation with body surface potential mapping and self-organizing maps.
Physiol Meas, 2003; 24: 805-816.
Abstract
Paulussen AD, Gilissen RA, Armstrong M, Doevendans PA, Verhasselt P, Smeets HJ, Schulze-Bahr E, Haverkamp W , Breithardt G, Cohen N, Aerssens J:
Genetic variations of KCNQ1, KCNH2, SCN5A, KCNE1, and KCNE2 in drug-induced long QT syndrome patients.
J Mol Med 2004; 82:182-188.
Abstract
Milberg P, Ramtin S, Mönnig G, Osada N, Wasmer K, Breithardt G, Haverkamp W, Eckardt L:
Comparison of the in vitro electrophysiologic and proarrhythmic effects of amiodarone and sotalol in a rabbit model of acute atrioventricular block.
J Cardiovasc Pharmacol 2004; 44:278-286.
Abstract
Milberg P, Reinsch N, Osada N, Wasmer K, Mönnig G, Stypmann J, Breithardt G, Haverkamp W, Eckardt L:
Verapamil prevents torsade de pointes by reduction of transmural dispersion of repolarization and suppression of early afterdepolarizations in an intact heart model of LQT3.
Basic Res Cardiol. 2005; 100:365-71.
Abstract
Titier K, Girodet PO, Verdoux H, Molimard M, Begaud B, Haverkamp W , Lader M, Moore N:
Atypical antipsychotics: from potassium channels to torsade de pointes and sudden death.
Drug Saf 2005; 28:35-51.
Abstract
Reinhardt L, Haverkamp W:
Herzfrequenzkorrektur des QT-Intervalls nach Bazett: Mythos oder Logos ?
Deutsche Zeitschrift für klinische Forschung 3/4-2006; 61-63.
Haverkamp W , Deuschle M:
Antipsychotikainduzierte QT-Verlängerung.
Der Nervenarzt 2006; 77:276-288.
Abstract
Milberg P, Fleischer D, Stypmann J, Osada N, Mönnig G, Engelen MA, Bruch C, Breithardt G, Haverkamp W , Eckardt L:
Reduced repolarization reserve due to anthracycline therapy facilitates torsade de pointes induced by I(Kr) blockers.
Basic Res Cardiol. 2006 Jul 4; [Epub ahead of print].
Abstract
Wedekind H, Bajanowski T, Friederich P, Breithardt G, Wulfing T, Siebrands C, Engeland B, Mönnig G, Haverkamp W , Brinkmann B, Schulze-Bahr E:
Sudden infant death syndrome and long QT syndrome: an epidemiological and genetic study.
Int J Legal Med. 2006 May; 120(3):129-37. Epub 2005 Jul 13.
Abstract
Haverkamp W:
Congenital long QT syndrome.
Herz 2007 May; 32(3): 201-205. Review
Abstract
Blaschke D, Parwani AS, Huemer M, Rolf S, Boldt LH, Dietz R, Haverkamp W:
Torsade de pointes during combined treatment with risperidone and citalopram.
Pharmacopsychiatry. 2007 Nov;40(6):294-5.
Abstract
Bass AS, Darpo B, Breidenbach A, Haverkamp W, et al.:
International Life Sciences Institute (Health and Environmental Sciences Institute, HESI) initiative on moving towards better predictors of drug-induced torsades de pointes.
Br J Pharmacol 2008;154:1491-1501.
Abstract
Huemer M, Boldt LH, Rolf S, Blaschke D, Parwani A, Haverkamp W:
Sustained monomorphic ventricular tachycardia after adenosine infusion.
Int J Cardiol 2009;131(3):e97-100.
Abstract
Posch MG, Perrot A, Geier C, Haverkamp W, et al.:
Genetic deletion of arginine 14 in phospholamban causes dilated cardiomyopathy with attenuated electrocardiographic R amplitudes.
Heart Rhythm. 2009 Apr;6(4):480-6.
Abstract
Zellerhoff S, Pistulli R, Mönnig G, Haverkamp W, et al.:
Atrial Arrhythmias in long-QT syndrome under daily life conditions: a nested case control study.
J Cardiovasc Electrophysiol. 2009 Apr;20(4):401-7.
Abstract
 
 
© Copyright 2006 - 2017 ExCard Research GmbH